Kyverna Completes Miv-cel BLA Submission in SPS

Company Kyverna Therapeutics Event Type BLA submission completed; priority review requested Modality Autologous CD19 CAR T Asset Mivocabtagene autoleucel (miv-cel) Target CD19 Disease Area Stiff person syndrome Summary Kyverna disclosed November 12 that it completed its rolling FDA biologics license application for mivocabtagene autoleucel in…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *